Keywords
Last Name

Vassilis I. Zannis, PhD

TitleProfessor
InstitutionBoston University School of Medicine
DepartmentMedicine
DivisionCardiovascular Medicine
Address700 Albany St Ctr for Adv Biomed Res
Boston MA 02118
Phone(617) 638-5085
ORCID ORCID Icon0000-0002-1295-7155
Other Positions
TitleProfessor
InstitutionBoston University School of Medicine
DepartmentBiochemistry

TitleGraduate Faculty (Primary Mentor of Grad Students)
InstitutionBoston University School of Medicine, Graduate Medical Sciences

 Research Expertise & Professional Interests
The major focus of our research is on the structure and functions of apoA-I and apoE in relation to the biogenesis of HDL, atherosclerosis and Alzheimer's disease. Using adenovirus-mediated gene transfer in apoA-I-deficient mice, we have established that apoA-I mutations inhibit discrete steps in a pathway that leads to the biogenesis and remodeling of HDL. To this point, five discrete categories of apoA-I mutants have been characterized that may affect the interactions of apoA-I with ABCA1 or LCAT or may influence the plasma PLTP activity or may cause various forms of dyslipidemia. Biogenesis of HDL is not a unique property of apoA-I. Using adenovirus-mediated gene transfer of apoE in apoA-I- or ABCA1-deficient mice, we have established that apoE also participates in a novel pathway of biogenesis of apoE-containing HDL particles. This process requires the functions of the ABCA1 lipid transporter and LCAT and it is promoted by substitution of hydrophobic residues in the 261 to 269 region of apoE by Ala. The apoE-containing HDL particles formed in the circulation may have atheroprotective properties. ApoE-containing HDL may also have important biological functions in the brain that confer protection from Alzheimer’s disease.

 Self-Described Keywords
  • biochemistry
  • gene therapy
  • molecular biology
  • molecular genetics
 Publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Fotakis P, Tiniakou I, Kateifides AK, Gkolfinopoulou C, Chroni A, Stratikos E, Zannis VI, Kardassis D. Significance of the hydrophobic residues 225-230 of apoA-I for the biogenesis of HDL. J Lipid Res. 2013 Dec; 54(12):3293-302.
    View in: PubMed
  2. Fotakis P, Kateifides AK, Gkolfinopoulou C, Georgiadou D, Beck M, Gründler K, Chroni A, Stratikos E, Kardassis D, Zannis VI. Role of the hydrophobic and charged residues in the 218-226 region of apoA-I in the biogenesis of HDL. J Lipid Res. 2013 Dec; 54(12):3281-92.
    View in: PubMed
  3. Georgiadou D, Chroni A, Drosatos K, Kypreos KE, Zannis VI, Stratikos E. Allele-dependent thermodynamic and structural perturbations in ApoE variants associated with the correction of dyslipidemia and formation of spherical ApoE-containing HDL particles. Atherosclerosis. 2013 Feb; 226(2):385-91.
    View in: PubMed
  4. Duka A, Fotakis P, Georgiadou D, Kateifides A, Tzavlaki K, von Eckardstein L, Stratikos E, Kardassis D, Zannis VI. ApoA-IV promotes the biogenesis of apoA-IV-containing HDL particles with the participation of ABCA1 and LCAT. J Lipid Res. 2013 Jan; 54(1):107-15.
    View in: PubMed
  5. Lampropoulou A, Zannis VI, Kypreos KE. Pharmacodynamic and pharmacokinetic analysis of apoE4 [L261A, W264A, F265A, L268A, V269A], a recombinant apolipoprotein E variant with improved biological properties. Biochem Pharmacol. 2012 Dec 1; 84(11):1451-8.
    View in: PubMed
  6. Dafnis I, Tzinia AK, Tsilibary EC, Zannis VI, Chroni A. An apolipoprotein E4 fragment affects matrix metalloproteinase 9, tissue inhibitor of metalloproteinase 1 and cytokine levels in brain cell lines. Neuroscience. 2012 May 17; 210:21-32.
    View in: PubMed
  7. Koupenova M, Johnston-Cox H, Vezeridis A, Gavras H, Yang D, Zannis V, Ravid K. A2b adenosine receptor regulates hyperlipidemia and atherosclerosis. Circulation. 2012 Jan 17; 125(2):354-63.
    View in: PubMed
  8. Georgiadou D, Chroni A, Vezeridis A, Zannis VI, Stratikos E. Biophysical analysis of apolipoprotein E3 variants linked with development of type III hyperlipoproteinemia. PLoS One. 2011; 6(11):e27037.
    View in: PubMed
  9. Biedzka-Sarek M, Metso J, Kateifides A, Meri T, Jokiranta TS, Muszynski A, Radziejewska-Lebrecht J, Zannis V, Skurnik M, Jauhiainen M. Apolipoprotein A-I exerts bactericidal activity against Yersinia enterocolitica serotype O:3. J Biol Chem. 2011 Nov 4; 286(44):38211-9.
    View in: PubMed
  10. Drosatos K, Drosatos-Tampakaki Z, Khan R, Homma S, Schulze PC, Zannis VI, Goldberg IJ. Inhibition of c-Jun-N-terminal kinase increases cardiac peroxisome proliferator-activated receptor alpha expression and fatty acid oxidation and prevents lipopolysaccharide-induced heart dysfunction. J Biol Chem. 2011 Oct 21; 286(42):36331-9.
    View in: PubMed
  11. Vezeridis AM, Chroni A, Zannis VI. Domains of apoE4 required for the biogenesis of apoE-containing HDL. Ann Med. 2011 Jun; 43(4):302-11.
    View in: PubMed
  12. Haase CL, Frikke-Schmidt R, Nordestgaard BG, Kateifides AK, Kardassis D, Nielsen LB, Andersen CB, Køber L, Johnsen AH, Grande P, Zannis VI, Tybjaerg-Hansen A. Mutation in APOA1 predicts increased risk of ischaemic heart disease and total mortality without low HDL cholesterol levels. J Intern Med. 2011 Aug; 270(2):136-46.
    View in: PubMed
  13. Kateifides AK, Gorshkova IN, Duka A, Chroni A, Kardassis D, Zannis VI. Alteration of negatively charged residues in the 89 to 99 domain of apoA-I affects lipid homeostasis and maturation of HDL. J Lipid Res. 2011 Jul; 52(7):1363-72.
    View in: PubMed
  14. Ohnsorg PM, Rohrer L, Perisa D, Kateifides A, Chroni A, Kardassis D, Zannis VI, von Eckardstein A. Carboxyl terminus of apolipoprotein A-I (ApoA-I) is necessary for the transport of lipid-free ApoA-I but not prelipidated ApoA-I particles through aortic endothelial cells. J Biol Chem. 2011 Mar 11; 286(10):7744-54.
    View in: PubMed
  15. Dafnis I, Stratikos E, Tzinia A, Tsilibary EC, Zannis VI, Chroni A. An apolipoprotein E4 fragment can promote intracellular accumulation of amyloid peptide beta 42. J Neurochem. 2010 Nov; 115(4):873-84.
    View in: PubMed
  16. Vezeridis AM, Drosatos K, Zannis VI. Molecular etiology of a dominant form of type III hyperlipoproteinemia caused by R142C substitution in apoE4. J Lipid Res. 2011 Jan; 52(1):45-56.
    View in: PubMed
  17. Mosialou I, Zannis VI, Kardassis D. Regulation of human apolipoprotein m gene expression by orphan and ligand-dependent nuclear receptors. J Biol Chem. 2010 Oct 1; 285(40):30719-30.
    View in: PubMed
  18. Iliopoulos D, Drosatos K, Hiyama Y, Goldberg IJ, Zannis VI. MicroRNA-370 controls the expression of microRNA-122 and Cpt1alpha and affects lipid metabolism. J Lipid Res. 2010 Jun; 51(6):1513-23.
    View in: PubMed
  19. Sanoudou D, Duka A, Drosatos K, Hayes KC, Zannis VI. Role of Esrrg in the fibrate-mediated regulation of lipid metabolism genes in human ApoA-I transgenic mice. Pharmacogenomics J. 2010 Jun; 10(3):165-79.
    View in: PubMed
  20. Gorshkova IN, Kypreos KE, Gantz DL, Zannis VI, Atkinson D. Biophysical properties of apolipoprotein E4 variants: implications in molecular mechanisms of correction of hypertriglyceridemia. Biochemistry. 2008 Nov 25; 47(47):12644-54.
    View in: PubMed
  21. Chroni A, Pyrpassopoulos S, Thanassoulas A, Nounesis G, Zannis VI, Stratikos E. Biophysical analysis of progressive C-terminal truncations of human apolipoprotein E4: insights into secondary structure and unfolding properties. Biochemistry. 2008 Sep 2; 47(35):9071-80.
    View in: PubMed
  22. Zannis VI, Koukos G, Drosatos K, Vezeridis A, Zanni EE, Kypreos KE, Chroni A. Discrete roles of apoA-I and apoE in the biogenesis of HDL species: lessons learned from gene transfer studies in different mouse models. Ann Med. 2008; 40 Suppl 1:14-28.
    View in: PubMed
  23. Nieland TJ, Shaw JT, Jaipuri FA, Duffner JL, Koehler AN, Banakos S, Zannis VI, Kirchhausen T, Krieger M. Identification of the molecular target of small molecule inhibitors of HDL receptor SR-BI activity. Biochemistry. 2008 Jan 8; 47(1):460-72.
    View in: PubMed
  24. Thymiakou E, Zannis VI, Kardassis D. Physical and functional interactions between liver X receptor/retinoid X receptor and Sp1 modulate the transcriptional induction of the human ATP binding cassette transporter A1 gene by oxysterols and retinoids. Biochemistry. 2007 Oct 16; 46(41):11473-83.
    View in: PubMed
  25. Koukos G, Chroni A, Duka A, Kardassis D, Zannis VI. LCAT can rescue the abnormal phenotype produced by the natural ApoA-I mutations (Leu141Arg)Pisa and (Leu159Arg)FIN. Biochemistry. 2007 Sep 18; 46(37):10713-21.
    View in: PubMed
  26. Koukos G, Chroni A, Duka A, Kardassis D, Zannis VI. Naturally occurring and bioengineered apoA-I mutations that inhibit the conversion of discoidal to spherical HDL: the abnormal HDL phenotypes can be corrected by treatment with LCAT. Biochem J. 2007 Aug 15; 406(1):167-74.
    View in: PubMed
  27. Drosatos K, Kypreos KE, Zannis VI. Residues Leu261, Trp264, and Phe265 account for apolipoprotein E-induced dyslipidemia and affect the formation of apolipoprotein E-containing high-density lipoprotein. Biochemistry. 2007 Aug 21; 46(33):9645-53.
    View in: PubMed
  28. Gafencu AV, Robciuc MR, Fuior E, Zannis VI, Kardassis D, Simionescu M. Inflammatory signaling pathways regulating ApoE gene expression in macrophages. J Biol Chem. 2007 Jul 27; 282(30):21776-85.
    View in: PubMed
  29. Drosatos K, Sanoudou D, Kypreos KE, Kardassis D, Zannis VI. A dominant negative form of the transcription factor c-Jun affects genes that have opposing effects on lipid homeostasis in mice. J Biol Chem. 2007 Jul 6; 282(27):19556-64.
    View in: PubMed
  30. Chroni A, Koukos G, Duka A, Zannis VI. The carboxy-terminal region of apoA-I is required for the ABCA1-dependent formation of alpha-HDL but not prebeta-HDL particles in vivo. Biochemistry. 2007 May 15; 46(19):5697-708.
    View in: PubMed
  31. Kypreos KE, Zannis VI. Pathway of biogenesis of apolipoprotein E-containing HDL in vivo with the participation of ABCA1 and LCAT. Biochem J. 2007 Apr 15; 403(2):359-67.
    View in: PubMed
  32. Nikolaidou-Neokosmidou V, Zannis VI, Kardassis D. Inhibition of hepatocyte nuclear factor 4 transcriptional activity by the nuclear factor kappaB pathway. Biochem J. 2006 Sep 15; 398(3):439-50.
    View in: PubMed
  33. Singaraja RR, Visscher H, James ER, Chroni A, Coutinho JM, Brunham LR, Kang MH, Zannis VI, Chimini G, Hayden MR. Specific mutations in ABCA1 have discrete effects on ABCA1 function and lipid phenotypes both in vivo and in vitro. Circ Res. 2006 Aug 18; 99(4):389-97.
    View in: PubMed
  34. Zannis VI, Chroni A, Krieger M. Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL. J Mol Med (Berl). 2006 Apr; 84(4):276-94.
    View in: PubMed
  35. Gorshkova IN, Liu T, Kan HY, Chroni A, Zannis VI, Atkinson D. Structure and stability of apolipoprotein a-I in solution and in discoidal high-density lipoprotein probed by double charge ablation and deletion mutation. Biochemistry. 2006 Jan 31; 45(4):1242-54.
    View in: PubMed
  36. Kypreos KE, Zannis VI. LDL receptor deficiency or apoE mutations prevent remnant clearance and induce hypertriglyceridemia in mice. J Lipid Res. 2006 Mar; 47(3):521-9.
    View in: PubMed
  37. Chroni A, Duka A, Kan HY, Liu T, Zannis VI. Point mutations in apolipoprotein A-I mimic the phenotype observed in patients with classical lecithin:cholesterol acyltransferase deficiency. Biochemistry. 2005 Nov 1; 44(43):14353-66.
    View in: PubMed
  38. Chroni A, Nieland TJ, Kypreos KE, Krieger M, Zannis VI. SR-BI mediates cholesterol efflux via its interactions with lipid-bound ApoE. Structural mutations in SR-BI diminish cholesterol efflux. Biochemistry. 2005 Oct 4; 44(39):13132-43.
    View in: PubMed
  39. Gerritsen G, Rensen PC, Kypreos KE, Zannis VI, Havekes LM, Willems van Dijk K. ApoC-III deficiency prevents hyperlipidemia induced by apoE overexpression. J Lipid Res. 2005 Jul; 46(7):1466-73.
    View in: PubMed
  40. Chroni A, Kan HY, Shkodrani A, Liu T, Zannis VI. Deletions of helices 2 and 3 of human apoA-I are associated with severe dyslipidemia following adenovirus-mediated gene transfer in apoA-I-deficient mice. Biochemistry. 2005 Mar 15; 44(10):4108-17.
    View in: PubMed
  41. Kypreos KE, van Dijk KW, Havekes LM, Zannis VI. Generation of a recombinant apolipoprotein E variant with improved biological functions: hydrophobic residues (LEU-261, TRP-264, PHE-265, LEU-268, VAL-269) of apoE can account for the apoE-induced hypertriglyceridemia. J Biol Chem. 2005 Feb 25; 280(8):6276-84.
    View in: PubMed
  42. Chroni A, Kan HY, Kypreos KE, Gorshkova IN, Shkodrani A, Zannis VI. Substitutions of glutamate 110 and 111 in the middle helix 4 of human apolipoprotein A-I (apoA-I) by alanine affect the structure and in vitro functions of apoA-I and induce severe hypertriglyceridemia in apoA-I-deficient mice. Biochemistry. 2004 Aug 17; 43(32):10442-57.
    View in: PubMed
  43. Kan HY, Georgopoulos S, Zanni M, Shkodrani A, Tzatsos A, Xie HX, Zannis VI. Contribution of the hormone-response elements of the proximal ApoA-I promoter, ApoCIII enhancer, and C/EBP binding site of the proximal ApoA-I promoter to the hepatic and intestinal expression of the ApoA-I and ApoCIII genes in transgenic mice. Biochemistry. 2004 May 4; 43(17):5084-93.
    View in: PubMed
  44. Nieland TJ, Chroni A, Fitzgerald ML, Maliga Z, Zannis VI, Kirchhausen T, Krieger M. Cross-inhibition of SR-BI- and ABCA1-mediated cholesterol transport by the small molecules BLT-4 and glyburide. J Lipid Res. 2004 Jul; 45(7):1256-65.
    View in: PubMed
  45. Zannis VI, Chroni A, Kypreos KE, Kan HY, Cesar TB, Zanni EE, Kardassis D. Probing the pathways of chylomicron and HDL metabolism using adenovirus-mediated gene transfer. Curr Opin Lipidol. 2004 Apr; 15(2):151-66.
    View in: PubMed
  46. Chroni A, Liu T, Fitzgerald ML, Freeman MW, Zannis VI. Cross-linking and lipid efflux properties of apoA-I mutants suggest direct association between apoA-I helices and ABCA1. Biochemistry. 2004 Feb 24; 43(7):2126-39.
    View in: PubMed
  47. Hatzivassiliou E, Koukos G, Ribeiro A, Zannis V, Kardassis D. Functional specificity of two hormone response elements present on the human apoA-II promoter that bind retinoid X receptor alpha/thyroid receptor beta heterodimers for retinoids and thyroids: synergistic interactions between thyroid receptor beta and upstream stimulatory factor 2a. Biochem J. 2003 Dec 1; 376(Pt 2):423-31.
    View in: PubMed
  48. Fitzgerald ML, Morris AL, Chroni A, Mendez AJ, Zannis VI, Freeman MW. ABCA1 and amphipathic apolipoproteins form high-affinity molecular complexes required for cholesterol efflux. J Lipid Res. 2004 Feb; 45(2):287-94.
    View in: PubMed
  49. Li X, Kypreos K, Zanni EE, Zannis V. Domains of apoE required for binding to apoE receptor 2 and to phospholipids: implications for the functions of apoE in the brain. Biochemistry. 2003 Sep 9; 42(35):10406-17.
    View in: PubMed
  50. Kypreos KE, Li X, van Dijk KW, Havekes LM, Zannis VI. Molecular mechanisms of type III hyperlipoproteinemia: The contribution of the carboxy-terminal domain of ApoE can account for the dyslipidemia that is associated with the E2/E2 phenotype. Biochemistry. 2003 Aug 26; 42(33):9841-53.
    View in: PubMed
  51. Kardassis D, Roussou A, Papakosta P, Boulias K, Talianidis I, Zannis VI. Synergism between nuclear receptors bound to specific hormone response elements of the hepatic control region-1 and the proximal apolipoprotein C-II promoter mediate apolipoprotein C-II gene regulation by bile acids and retinoids. Biochem J. 2003 Jun 1; 372(Pt 2):291-304.
    View in: PubMed
  52. Masana L, Madan T, Visvikis S, Sass C, Baranova H, Bonnet J, Dembinska A, Ehrlich H, Gueyffier F, Schmitz G, Siest G, Zannis V. Which, and how limited number of polymorphisms should be selected per disease, risk assessment, health profile or biological system? Clin Chem Lab Med. 2003 Apr; 41(4):554-8.
    View in: PubMed
  53. Zannis VI, Liu T, Zanni M, Kan HY, Kardassis D. Regulatory gene mutations affecting apolipoprotein gene expression: functions and regulatory behavior of known genes may guide future pharmacogenomic approaches to therapy. Clin Chem Lab Med. 2003 Apr; 41(4):411-24.
    View in: PubMed
  54. Chou WC, Prokova V, Shiraishi K, Valcourt U, Moustakas A, Hadzopoulou-Cladaras M, Zannis VI, Kardassis D. Mechanism of a transcriptional cross talk between transforming growth factor-beta-regulated Smad3 and Smad4 proteins and orphan nuclear receptor hepatocyte nuclear factor-4. Mol Biol Cell. 2003 Mar; 14(3):1279-94.
    View in: PubMed
  55. Chroni A, Liu T, Gorshkova I, Kan HY, Uehara Y, Von Eckardstein A, Zannis VI. The central helices of ApoA-I can promote ATP-binding cassette transporter A1 (ABCA1)-mediated lipid efflux. Amino acid residues 220-231 of the wild-type ApoA-I are required for lipid efflux in vitro and high density lipoprotein formation in vivo. J Biol Chem. 2003 Feb 28; 278(9):6719-30.
    View in: PubMed
  56. Gerritsen G, Kypreos KE, van der Zee A, Teusink B, Zannis VI, Havekes LM, van Dijk KW. Hyperlipidemia in APOE2 transgenic mice is ameliorated by a truncated apoE variant lacking the C-terminal domain. J Lipid Res. 2003 Feb; 44(2):408-14.
    View in: PubMed
  57. Gorshkova IN, Liu T, Zannis VI, Atkinson D. Lipid-free structure and stability of apolipoprotein A-I: probing the central region by mutation. Biochemistry. 2002 Aug 20; 41(33):10529-39.
    View in: PubMed
  58. Georgopoulos S, McKee A, Kan HY, Zannis VI. Generation and characterization of two transgenic mouse lines expressing human ApoE2 in neurons and glial cells. Biochemistry. 2002 Jul 30; 41(30):9293-301.
    View in: PubMed
  59. Liu T, Krieger M, Kan HY, Zannis VI. The effects of mutations in helices 4 and 6 of ApoA-I on scavenger receptor class B type I (SR-BI)-mediated cholesterol efflux suggest that formation of a productive complex between reconstituted high density lipoprotein and SR-BI is required for efficient lipid transport. J Biol Chem. 2002 Jun 14; 277(24):21576-84.
    View in: PubMed
  60. Li X, Kan HY, Lavrentiadou S, Krieger M, Zannis V. Reconstituted discoidal ApoE-phospholipid particles are ligands for the scavenger receptor BI. The amino-terminal 1-165 domain of ApoE suffices for receptor binding. J Biol Chem. 2002 Jun 14; 277(24):21149-57.
    View in: PubMed
  61. Kardassis D, Falvey E, Tsantili P, Hadzopoulou-Cladaras M, Zannis V. Direct physical interactions between HNF-4 and Sp1 mediate synergistic transactivation of the apolipoprotein CIII promoter. Biochemistry. 2002 Jan 29; 41(4):1217-28.
    View in: PubMed
  62. Reardon CA, Kan HY, Cabana V, Blachowicz L, Lukens JR, Wu Q, Liadaki K, Getz GS, Zannis VI. In vivo studies of HDL assembly and metabolism using adenovirus-mediated transfer of ApoA-I mutants in ApoA-I-deficient mice. Biochemistry. 2001 Nov 13; 40(45):13670-80.
    View in: PubMed
  63. Kypreos KE, Teusink B, Van Dijk KW, Havekes LM, Zannis VI. Analysis of the structure and function relationship of the human apolipoprotein E in vivo, using adenovirus-mediated gene transfer. FASEB J. 2001 Jul; 15(9):1598-600.
    View in: PubMed
  64. Kypreos KE, Morani P, van Dijk KW, Havekes LM, Zannis VI. The amino-terminal 1-185 domain of apoE promotes the clearance of lipoprotein remnants in vivo. The carboxy-terminal domain is required for induction of hyperlipidemia in normal and apoE-deficient mice. Biochemistry. 2001 May 22; 40(20):6027-35.
    View in: PubMed
  65. Zannis VI, Kan HY, Kritis A, Zanni EE, Kardassis D. Transcriptional regulatory mechanisms of the human apolipoprotein genes in vitro and in vivo. Curr Opin Lipidol. 2001 Apr; 12(2):181-207.
    View in: PubMed
  66. Zannis VI, Kan HY, Kritis A, Zanni E, Kardassis D. Transcriptional regulation of the human apolipoprotein genes. Front Biosci. 2001 Mar 1; 6:D456-504.
    View in: PubMed
  67. Kypreos KE, van Dijk KW, van Der Zee A, Havekes LM, Zannis VI. Domains of apolipoprotein E contributing to triglyceride and cholesterol homeostasis in vivo. Carboxyl-terminal region 203-299 promotes hepatic very low density lipoprotein-triglyceride secretion. J Biol Chem. 2001 Jun 8; 276(23):19778-86.
    View in: PubMed
  68. Herscovitz H, Derksen A, Walsh MT, McKnight CJ, Gantz DL, Hadzopoulou-Cladaras M, Zannis V, Curry C, Small DM. The N-terminal 17% of apoB binds tightly and irreversibly to emulsions modeling nascent very low density lipoproteins. J Lipid Res. 2001 Jan; 42(1):51-9.
    View in: PubMed
  69. Kardassis D, Pardali K, Zannis VI. SMAD proteins transactivate the human ApoCIII promoter by interacting physically and functionally with hepatocyte nuclear factor 4. J Biol Chem. 2000 Dec 29; 275(52):41405-14.
    View in: PubMed
  70. Gorshkova IN, Liadaki K, Gursky O, Atkinson D, Zannis VI. Probing the lipid-free structure and stability of apolipoprotein A-I by mutation. Biochemistry. 2000 Dec 26; 39(51):15910-9.
    View in: PubMed
  71. Georgopoulos S, Kan HY, Reardon-Alulis C, Zannis V. The SP1 sites of the human apoCIII enhancer are essential for the expression of the apoCIII gene and contribute to the hepatic and intestinal expression of the apoA-I gene in transgenic mice. Nucleic Acids Res. 2000 Dec 15; 28(24):4919-29.
    View in: PubMed
  72. Kan HY, Georgopoulos S, Zannis V. A hormone response element in the human apolipoprotein CIII (ApoCIII) enhancer is essential for intestinal expression of the ApoA-I and ApoCIII genes and contributes to the hepatic expression of the two linked genes in transgenic mice. J Biol Chem. 2000 Sep 29; 275(39):30423-31.
    View in: PubMed
  73. Carraway M, Herscovitz H, Zannis V, Small DM. Specificity of lipid incorporation is determined by sequences in the N-terminal 37 of apoB. Biochemistry. 2000 Aug 15; 39(32):9737-45.
    View in: PubMed
  74. Segrest JP, Harvey SC, Zannis V. Detailed molecular model of apolipoprotein A-I on the surface of high-density lipoproteins and its functional implications. Trends Cardiovasc Med. 2000 Aug; 10(6):246-52.
    View in: PubMed
  75. Liadaki KN, Liu T, Xu S, Ishida BY, Duchateaux PN, Krieger JP, Kane J, Krieger M, Zannis VI. Binding of high density lipoprotein (HDL) and discoidal reconstituted HDL to the HDL receptor scavenger receptor class B type I. Effect of lipid association and APOA-I mutations on receptor binding. J Biol Chem. 2000 Jul 14; 275(28):21262-71.
    View in: PubMed
  76. Segrest JP, Li L, Anantharamaiah GM, Harvey SC, Liadaki KN, Zannis V. Structure and function of apolipoprotein A-I and high-density lipoprotein. Curr Opin Lipidol. 2000 Apr; 11(2):105-15.
    View in: PubMed
  77. Zannis VI, Cohen J. Old and new players in the lipoprotein system. Curr Opin Lipidol. 2000 Apr; 11(2):101-3.
    View in: PubMed
  78. Aleshkov SB, Li X, Lavrentiadou SN, Zannis VI. Contribution of cysteine 158, the glycosylation site threonine 194, the amino- and carboxy-terminal domains of apolipoprotein E in the binding to amyloid peptide beta (1-40). Biochemistry. 1999 Jul 13; 38(28):8918-25.
    View in: PubMed
  79. Pissios P, Kan HY, Nagaoka S, Zannis VI. SREBP-1 binds to multiple sites and transactivates the human ApoA-II promoter in vitro : SREBP-1 mutants defective in DNA binding or transcriptional activation repress ApoA-II promoter activity. Arterioscler Thromb Vasc Biol. 1999 Jun; 19(6):1456-69.
    View in: PubMed
  80. Le Beyec J, Chauffeton V, Kan HY, Janvier PL, Cywiner-Golenzer C, Chatelet FP, Kalopissis AD, Zannis V, Chambaz J, Pinçon-Raymond M, Cardot P. The -700/-310 fragment of the apolipoprotein A-IV gene combined with the -890/-500 apolipoprotein C-III enhancer is sufficient to direct a pattern of gene expression similar to that for the endogenous apolipoprotein A-IV gene. J Biol Chem. 1999 Feb 19; 274(8):4954-61.
    View in: PubMed
  81. Kan HY, Pissios P, Chambaz J, Zannis VI. DNA binding specificity and transactivation properties of SREBP-2 bound to multiple sites on the human apoA-II promoter. Nucleic Acids Res. 1999 Feb 15; 27(4):1104-17.
    View in: PubMed
  82. Lavrentiadou SN, Hadzopoulou-Cladaras M, Kardassis D, Zannis VI. Binding specificity and modulation of the human ApoCIII promoter activity by heterodimers of ligand-dependent nuclear receptors. Biochemistry. 1999 Jan 19; 38(3):964-75.
    View in: PubMed
  83. Hadzopoulou-Cladaras M, Lavrentiadou SN, Zannis VI, Kardassis D. Transactivation of the ApoCIII promoter by ATF-2 and repression by members of the Jun family. Biochemistry. 1998 Oct 6; 37(40):14078-87.
    View in: PubMed
  84. Kardassis D, Sacharidou E, Zannis VI. Transactivation of the human apolipoprotein CII promoter by orphan and ligand-dependent nuclear receptors. The regulatory element CIIC is a thyroid hormone response element. J Biol Chem. 1998 Jul 10; 273(28):17810-6.
    View in: PubMed
  85. Vorgia P, Zannis VI, Kardassis D. A short proximal promoter and the distal hepatic control region-1 (HCR-1) contribute to the liver specificity of the human apolipoprotein C-II gene. Hepatic enhancement by HCR-1 requires two proximal hormone response elements which have different binding specificities for orphan receptors HNF-4, ARP-1, and EAR-2. J Biol Chem. 1998 Feb 13; 273(7):4188-96.
    View in: PubMed
  86. Lacorte JM, Ktistaki E, Beigneux A, Zannis VI, Chambaz J, Talianidis I. Activation of CAAT enhancer-binding protein delta (C/EBPdelta) by interleukin-1 negatively influences apolipoprotein C-III expression. J Biol Chem. 1997 Sep 19; 272(38):23578-84.
    View in: PubMed
  87. Aleshkov S, Abraham CR, Zannis VI. Interaction of nascent ApoE2, ApoE3, and ApoE4 isoforms expressed in mammalian cells with amyloid peptide beta (1-40). Relevance to Alzheimer's disease. Biochemistry. 1997 Aug 26; 36(34):10571-80.
    View in: PubMed
  88. Hatzivassiliou E, Cardot P, Zannis VI, Mitsialis SA. Ultraspiracle, a Drosophila retinoic X receptor alpha homologue, can mobilize the human thyroid hormone receptor to transactivate a human promoter. Biochemistry. 1997 Jul 29; 36(30):9221-31.
    View in: PubMed
  89. Laccotripe M, Makrides SC, Jonas A, Zannis VI. The carboxyl-terminal hydrophobic residues of apolipoprotein A-I affect its rate of phospholipid binding and its association with high density lipoprotein. J Biol Chem. 1997 Jul 11; 272(28):17511-22.
    View in: PubMed
  90. Xu S, Laccotripe M, Huang X, Rigotti A, Zannis VI, Krieger M. Apolipoproteins of HDL can directly mediate binding to the scavenger receptor SR-BI, an HDL receptor that mediates selective lipid uptake. J Lipid Res. 1997 Jul; 38(7):1289-98.
    View in: PubMed
  91. Kardassis D, Tzameli I, Hadzopoulou-Cladaras M, Talianidis I, Zannis V. Distal apolipoprotein C-III regulatory elements F to J act as a general modular enhancer for proximal promoters that contain hormone response elements. Synergism between hepatic nuclear factor-4 molecules bound to the proximal promoter and distal enhancer sites. Arterioscler Thromb Vasc Biol. 1997 Jan; 17(1):222-32.
    View in: PubMed
  92. Kritis AA, Argyrokastritis A, Moschonas NK, Power S, Katrakili N, Zannis VI, Cereghini S, Talianidis I. Isolation and characterization of a third isoform of human hepatocyte nuclear factor 4. Gene. 1996 Sep 16; 173(2):275-80.
    View in: PubMed
  93. Tzameli I, Zannis VI. Binding specificity and modulation of the ApoA-I promoter activity by homo- and heterodimers of nuclear receptors. J Biol Chem. 1996 Apr 5; 271(14):8402-15.
    View in: PubMed
  94. Kardassis D, Laccotripe M, Talianidis I, Zannis V. Transcriptional regulation of the genes involved in lipoprotein transport. The role of proximal promoters and long-range regulatory elements and factors in apolipoprotein gene regulation. Hypertension. 1996 Apr; 27(4):980-1008.
    View in: PubMed
  95. Talianidis I, Tambakaki A, Toursounova J, Zannis VI. Complex interactions between SP1 bound to multiple distal regulatory sites and HNF-4 bound to the proximal promoter lead to transcriptional activation of liver-specific human APOCIII gene. Biochemistry. 1995 Aug 15; 34(32):10298-309.
    View in: PubMed
  96. Herscovitz H, Kritis A, Talianidis I, Zanni E, Zannis V, Small DM. Murine mammary-derived cells secrete the N-terminal 41% of human apolipoprotein B on high density lipoprotein-sized lipoproteins containing a triacylglycerol-rich core. Proc Natl Acad Sci U S A. 1995 Jan 31; 92(3):659-63.
    View in: PubMed
  97. Ktistaki E, Lacorte JM, Katrakili N, Zannis VI, Talianidis I. Transcriptional regulation of the apolipoprotein A-IV gene involves synergism between a proximal orphan receptor response element and a distant enhancer located in the upstream promoter region of the apolipoprotein C-III gene. Nucleic Acids Res. 1994 Nov 11; 22(22):4689-96.
    View in: PubMed
  98. Cardot P, Pastier D, Lacorte JM, Mangeney M, Zannis VI, Chambaz J. Purification and characterization of nuclear factors binding to the negative regulatory element D of human apolipoprotein A-II promoter: a negative regulatory effect is reversed by GABP, an Ets-related protein. Biochemistry. 1994 Oct 11; 33(40):12139-48.
    View in: PubMed
  99. Lopez J, Roghani A, Bertrand J, Zanni E, Kalopissis A, Zannis VI, Chambaz J. Intracellular early and late modifications of human apolipoprotein A-II. Effect of glutamine- +1 to leucine substitution. Biochemistry. 1994 Apr 5; 33(13):4056-64.
    View in: PubMed
  100. Kritis AA, Ktistaki E, Barda D, Zannis VI, Talianidis I. An indirect negative autoregulatory mechanism involved in hepatocyte nuclear factor-1 gene expression. Nucleic Acids Res. 1993 Dec 25; 21(25):5882-9.
    View in: PubMed
  101. Cardot P, Chambaz J, Kardassis D, Cladaras C, Zannis VI. Factors participating in the liver-specific expression of the human apolipoprotein A-II gene and their significance for transcription. Biochemistry. 1993 Sep 7; 32(35):9080-93.
    View in: PubMed
  102. Zannis VI, Kardassis D, Zanni EE. Genetic mutations affecting human lipoproteins, their receptors, and their enzymes. Adv Hum Genet. 1993; 21:145-319.
    View in: PubMed
  103. Minnich A, Collet X, Roghani A, Cladaras C, Hamilton RL, Fielding CJ, Zannis VI. Site-directed mutagenesis and structure-function analysis of the human apolipoprotein A-I. Relation between lecithin-cholesterol acyltransferase activation and lipid binding. J Biol Chem. 1992 Aug 15; 267(23):16553-60.
    View in: PubMed
  104. Ladias JA, Hadzopoulou-Cladaras M, Kardassis D, Cardot P, Cheng J, Zannis V, Cladaras C. Transcriptional regulation of human apolipoprotein genes ApoB, ApoCIII, and ApoAII by members of the steroid hormone receptor superfamily HNF-4, ARP-1, EAR-2, and EAR-3. J Biol Chem. 1992 Aug 5; 267(22):15849-60.
    View in: PubMed
  105. Herscovitz H, Gantz D, Tercyak AM, Zannis VI, Small DM. Expression of human apolipoprotein E but not that of apolipoprotein A-I by mouse C127 cells is associated with increased secretion of lipids in the form of vesicles and discs. J Lipid Res. 1992 Jun; 33(6):791-803.
    View in: PubMed
  106. Kardassis D, Zannis VI, Cladaras C. Organization of the regulatory elements and nuclear activities participating in the transcription of the human apolipoprotein B gene. J Biol Chem. 1992 Apr 15; 267(11):7956.
    View in: PubMed
  107. Kardassis D, Zannis VI, Cladaras C. Organization of the regulatory elements and nuclear activities participating in the transcription of the human apolipoprotein B gene. J Biol Chem. 1992 Feb 5; 267(4):2622-32.
    View in: PubMed
  108. Cardot P, Chambaz J, Cladaras C, Zannis VI. Regulation of the human ApoA-II gene by the synergistic action of factors binding to the proximal and distal regulatory elements. J Biol Chem. 1991 Dec 25; 266(36):24460-70.
    View in: PubMed
  109. Herscovitz H, Hadzopoulou-Cladaras M, Walsh MT, Cladaras C, Zannis VI, Small DM. Expression, secretion, and lipid-binding characterization of the N-terminal 17% of apolipoprotein B. Proc Natl Acad Sci U S A. 1991 Aug 15; 88(16):7313-7.
    View in: PubMed
  110. Chambaz J, Cardot P, Pastier D, Zannis VI, Cladaras C. Promoter elements and factors required for hepatic transcription of the human ApoA-II gene. J Biol Chem. 1991 Jun 25; 266(18):11676-85.
    View in: PubMed
  111. Ogami K, Kardassis D, Cladaras C, Zannis VI. Purification and characterization of a heat stable nuclear factor CIIIB1 involved in the regulation of the human ApoC-III gene. J Biol Chem. 1991 May 25; 266(15):9640-6.
    View in: PubMed
  112. Hussain MM, Roghani A, Cladaras C, Zanni EE, Zannis VI. Secretion of lipid-poor nascent human apolipoprotein apoAI, apoCIII, and apoE by cell clones expressing the corresponding genes. Electrophoresis. 1991 Apr; 12(4):273-83.
    View in: PubMed
  113. Papazafiri P, Ogami K, Ramji DP, Nicosia A, Monaci P, Cladaras C, Zannis VI. Promoter elements and factors involved in hepatic transcription of the human ApoA-I gene positive and negative regulators bind to overlapping sites. J Biol Chem. 1991 Mar 25; 266(9):5790-7.
    View in: PubMed
  114. Lenich CM, Chobanian AV, Brecher P, Zannis VI. Effect of dietary cholesterol and alloxan-diabetes on tissue cholesterol and apolipoprotein E mRNA levels in the rabbit. J Lipid Res. 1991 Mar; 32(3):431-8.
    View in: PubMed
  115. Flordellis CS, Handy DE, Bresnahan MR, Zannis VI, Gavras H. Cloning and expression of a rat brain alpha 2B-adrenergic receptor. Proc Natl Acad Sci U S A. 1991 Feb 1; 88(3):1019-23.
    View in: PubMed
  116. Zannis VI, Kardassis D, Ogami K, Hadzopoulou-Cladaras M, Cladaras C. Transcriptional regulation of the human apolipoprotein genes. Adv Exp Med Biol. 1991; 285:1-23.
    View in: PubMed
  117. Kardassis D, Zannis VI, Cladaras C. Purification and characterization of the nuclear factor BA1. A transcriptional activator of the human apoB gene. J Biol Chem. 1990 Dec 15; 265(35):21733-40.
    View in: PubMed
  118. Ogami K, Hadzopoulou-Cladaras M, Cladaras C, Zannis VI. Promoter elements and factors required for hepatic and intestinal transcription of the human ApoCIII gene. J Biol Chem. 1990 Jun 15; 265(17):9808-15.
    View in: PubMed
  119. Flordellis CS, Castellano M, Franco R, Zannis VI, Gavras H. Expression of multiple alpha 2-adrenergic receptor messenger RNA species in rat tissues. Hypertension. 1990 Jun; 15(6 Pt 2):881-7.
    View in: PubMed
  120. Kardassis D, Hadzopoulou-Cladaras M, Ramji DP, Cortese R, Zannis VI, Cladaras C. Characterization of the promoter elements required for hepatic and intestinal transcription of the human apoB gene: definition of the DNA-binding site of a tissue-specific transcriptional factor. Mol Cell Biol. 1990 Jun; 10(6):2653-9.
    View in: PubMed
  121. Bresnahan MR, Flordellis CS, Vassilatis DK, Makrides SC, Zannis VI, Gavras H. High level of expression of functional human platelet alpha 2-adrenergic receptors in a stable mouse C127 cell line. Biochim Biophys Acta. 1990 May 22; 1052(3):439-45.
    View in: PubMed
  122. Hussain MM, Zannis VI. Intracellular modification of human apolipoprotein AII (apoAII) and sites of apoAII mRNA synthesis: comparison of apoAII with apoCII and apoCIII isoproteins. Biochemistry. 1990 Jan 9; 29(1):209-17.
    View in: PubMed
  123. Hussain MM, Zannis VI, Plaitakis A. Characterization of glutamate dehydrogenase isoproteins purified from the cerebellum of normal subjects and patients with degenerative neurological disorders, and from human neoplastic cell lines. J Biol Chem. 1989 Dec 5; 264(34):20730-5.
    View in: PubMed
  124. Zanni EE, Kouvatsi A, Hadzopoulou-Cladaras M, Krieger M, Zannis VI. Expression of ApoE gene in Chinese hamster cells with a reversible defect in O-glycosylation. Glycosylation is not required for apoE secretion. J Biol Chem. 1989 Jun 5; 264(16):9137-40.
    View in: PubMed
  125. Hussain MM, Zanni EE, Kelly M, Zannis VI. Synthesis, modification, and flotation properties of rat hepatocyte apolipoproteins. Biochim Biophys Acta. 1989 Jan 23; 1001(1):90-101.
    View in: PubMed
  126. Zannis VI. Molecular biology of human apolipoproteins B and E and associated diseases of lipoprotein metabolism. Adv Lipid Res. 1989; 23:1-64.
    View in: PubMed
  127. Roghani A, Zannis VI. Mutagenesis of the glycosylation site of human ApoCIII. O-linked glycosylation is not required for ApoCIII secretion and lipid binding. J Biol Chem. 1988 Dec 5; 263(34):17925-32.
    View in: PubMed
  128. Makrides SC, Mulinari R, Zannis VI, Gavras H. Regulation of renin gene expression in hypertensive rats. Hypertension. 1988 Oct; 12(4):405-10.
    View in: PubMed
  129. Roghani A, Zannis VI. Alterations of the glutamine residues of human apolipoprotein AI propeptide by in vitro mutagenesis. Characterization of the normal and mutant protein forms. Biochemistry. 1988 Sep 20; 27(19):7428-35.
    View in: PubMed
  130. Hussain MM, Bucher NL, Faris B, Franzblau C, Zannis VI. Tissue-specific posttranslational modification of rat apoE. Synthesis of sialated apoE forms by neonatal rat aortic smooth muscle cells. J Lipid Res. 1988 Jul; 29(7):915-23.
    View in: PubMed
  131. Lenich C, Brecher P, Makrides S, Chobanian A, Zannis VI. Apolipoprotein gene expression in the rabbit: abundance, size, and distribution of apolipoprotein mRNA species in different tissues. J Lipid Res. 1988 Jun; 29(6):755-64.
    View in: PubMed
  132. Mavrothalassitis G, Tzimagiorgis G, Mitsialis A, Zannis V, Plaitakis A, Papamatheakis J, Moschonas N. Isolation and characterization of cDNA clones encoding human liver glutamate dehydrogenase: evidence for a small gene family. Proc Natl Acad Sci U S A. 1988 May; 85(10):3494-8.
    View in: PubMed
  133. Makrides SC, Ruiz-Opazo N, Hayden M, Nussbaum AL, Breslow JL, Zannis VI. Sequence and expression of Tangier apoA-I gene. Eur J Biochem. 1988 Apr 15; 173(2):465-71.
    View in: PubMed
  134. Ruiz-Opazo N, Zannis VI. Expression of the human apolipoprotein A-I gene in rat myogenic L6E9 cells. DNA methylation and regulation of gene activity. J Biol Chem. 1988 Feb 5; 263(4):1739-44.
    View in: PubMed
  135. Zannis VI, Hussain MM, Hadzopoulou-Cladaras M, Kouvatsi A, Kardassis D, Cladaras C. Molecular biology of human apolipoprotein B and related diseases. Adv Exp Med Biol. 1988; 243:107-21.
    View in: PubMed
  136. Zanni EE, Zannis VI, Blum CB, Herbert PN, Breslow JL. Effect of egg cholesterol and dietary fats on plasma lipids, lipoproteins, and apoproteins of normal women consuming natural diets. J Lipid Res. 1987 May; 28(5):518-27.
    View in: PubMed
  137. Cladaras C, Hadzopoulou-Cladaras M, Felber BK, Pavlakis G, Zannis VI. The molecular basis of a familial apoE deficiency. An acceptor splice site mutation in the third intron of the deficient apoE gene. J Biol Chem. 1987 Feb 15; 262(5):2310-5.
    View in: PubMed
  138. Cladaras C, Hadzopoulou-Cladaras M, Nolte RT, Atkinson D, Zannis VI. The complete sequence and structural analysis of human apolipoprotein B-100: relationship between apoB-100 and apoB-48 forms. EMBO J. 1986 Dec 20; 5(13):3495-507.
    View in: PubMed
  139. Zannis VI, vanderSpek J, Silverman D. Intracellular modifications of human apolipoprotein E. J Biol Chem. 1986 Oct 15; 261(29):13415-21.
    View in: PubMed
  140. Cladaras C, Hadzopoulou-Cladaras M, Avila R, Nussbaum AL, Nicolosi R, Zannis VI. Complementary DNA derived structure of the amino-terminal domain of human apolipoprotein B and size of its messenger RNA transcript. Biochemistry. 1986 Sep 23; 25(19):5351-7.
    View in: PubMed
  141. Zanni EE, Stephan ZF, Zannis VI, Breslow JL, Hayes KC. ApoE distribution among lipoproteins of rhesus monkeys is modulated by dietary fat and cholesterol. J Nutr. 1986 Sep; 116(9):1611-9.
    View in: PubMed
  142. Karathanasis SK, Yunis I, Zannis VI. Structure, evolution, and tissue-specific synthesis of human apolipoprotein AIV. Biochemistry. 1986 Jul 1; 25(13):3962-70.
    View in: PubMed
  143. Karathanasis SK, Zannis VI, Breslow JL. Characterization of the apolipoprotein A-I-C-III gene complex. Methods Enzymol. 1986; 128:712-26.
    View in: PubMed
  144. Zannis VI. Genetic polymorphism in human apolipoprotein E. Methods Enzymol. 1986; 128:823-51.
    View in: PubMed
  145. Zannis VI, Karathanasis SK, Forbes GM, Breslow JL. Intra- and extracellular modifications of apolipoproteins. Methods Enzymol. 1986; 128:690-712.
    View in: PubMed
  146. Zannis VI, Nicolosi RJ, Jensen E, Breslow JL, Hayes KC. Plasma and hepatic apoE isoproteins of nonhuman primates. Differences in apoE among humans, apes, and New and Old World monkeys. J Lipid Res. 1985 Dec; 26(12):1421-30.
    View in: PubMed
  147. Zannis VI, Ordovas JM, Cladaras C, Cole FS, Forbes G, Schaefer EJ. mRNA and apolipoprotein E synthesis abnormalities in peripheral blood monocyte macrophages in familial apolipoprotein E deficiency. J Biol Chem. 1985 Oct 25; 260(24):12891-4.
    View in: PubMed
  148. Zannis VI, Cole FS, Jackson CL, Kurnit DM, Karathanasis SK. Distribution of apolipoprotein A-I, C-II, C-III, and E mRNA in fetal human tissues. Time-dependent induction of apolipoprotein E mRNA by cultures of human monocyte-macrophages. Biochemistry. 1985 Jul 30; 24(16):4450-5.
    View in: PubMed
  149. Karathanasis SK, Zannis VI, Breslow JL. Isolation and characterization of cDNA clones corresponding to two different human apoC-III alleles. J Lipid Res. 1985 Apr; 26(4):451-6.
    View in: PubMed
  150. Zannis VI, Breslow JL. Genetic mutations affecting human lipoprotein metabolism. Adv Hum Genet. 1985; 14:125-215, 383-6.
    View in: PubMed
  151. Nicolosi RJ, Zannis VI. Apolipoprotein A-I of primates. J Lipid Res. 1984 Sep; 25(9):879-87.
    View in: PubMed
  152. Zannis VI, McPherson J, Goldberger G, Karathanasis SK, Breslow JL. Synthesis, intracellular processing, and signal peptide of human apolipoprotein E. J Biol Chem. 1984 May 10; 259(9):5495-9.
    View in: PubMed
  153. Karathanasis SK, Zannis VI, Breslow JL. A DNA insertion in the apolipoprotein A-I gene of patients with premature atherosclerosis. Nature. 1983 Oct 27-Nov 2; 305(5937):823-5.
    View in: PubMed
  154. Karathanasis SK, Zannis VI, Breslow JL. Isolation and characterization of the human apolipoprotein A-I gene. Proc Natl Acad Sci U S A. 1983 Oct; 80(20):6147-51.
    View in: PubMed
  155. Fisher EA, Blum CB, Zannis VI, Breslow JL. Independent effects of dietary saturated fat and cholesterol on plasma lipids, lipoproteins, and apolipoprotein E. J Lipid Res. 1983 Aug; 24(8):1039-48.
    View in: PubMed
  156. Karathanasis SK, McPherson J, Zannis VI, Breslow JL. Linkage of human apolipoproteins A-I and C-III genes. Nature. 1983 Jul 28-Aug 3; 304(5924):371-3.
    View in: PubMed
  157. Zannis VI, Karathanasis SK, Keutmann HT, Goldberger G, Breslow JL. Intracellular and extracellular processing of human apolipoprotein A-I: secreted apolipoprotein A-I isoprotein 2 is a propeptide. Proc Natl Acad Sci U S A. 1983 May; 80(9):2574-8.
    View in: PubMed
  158. Karathanasis SK, Norum RA, Zannis VI, Breslow JL. An inherited polymorphism in the human apolipoprotein A-I gene locus related to the development of atherosclerosis. Nature. 1983 Feb 24; 301(5902):718-20.
    View in: PubMed
  159. Breslow JL, McPherson J, Nussbaum AL, Williams HW, Lofquist-Kahl F, Karathanasis SK, Zannis VI. Identification and DNA sequence of a human apolipoprotein E cDNA clone. J Biol Chem. 1982 Dec 25; 257(24):14639-41.
    View in: PubMed
  160. Breslow JL, Zannis VI, SanGiacomo TR, Third JL, Tracy T, Glueck CJ. Studies of familial type III hyperlipoproteinemia using as a genetic marker the apoE phenotype E2/2. J Lipid Res. 1982 Nov; 23(8):1224-35.
    View in: PubMed
  161. Breslow JL, Ross D, McPherson J, Williams H, Kurnit D, Nussbaum AL, Karathanasis SK, Zannis VI. Isolation and characterization of cDNA clones for human apolipoprotein A-I. Proc Natl Acad Sci U S A. 1982 Nov; 79(22):6861-5.
    View in: PubMed
  162. Zannis VI, Breslow JL, Utermann G, Mahley RW, Weisgraber KH, Havel RJ, Goldstein JL, Brown MS, Schonfeld G, Hazzard WR, Blum C. Proposed nomenclature of apoE isoproteins, apoE genotypes, and phenotypes. J Lipid Res. 1982 Aug; 23(6):911-4.
    View in: PubMed
  163. Zannis VI, Lees AM, Lees RS, Breslow JL. Abnormal apoprotein A-I isoprotein composition in patients with Tangier disease. J Biol Chem. 1982 May 10; 257(9):4978-86.
    View in: PubMed
  164. Zannis VI, Breslow JL. Apolipoprotein E. Mol Cell Biochem. 1982 Jan 16; 42(1):3-20.
    View in: PubMed
  165. Zannis VI, Kurnit DM, Breslow JL. Hepatic apo-A-I and apo-E and intestinal apo-A-I are synthesized in precursor isoprotein forms by organ cultures of human fetal tissues. J Biol Chem. 1982 Jan 10; 257(1):536-44.
    View in: PubMed
  166. Zannis VI, Breslow JL, SanGiacomo TR, Aden DP, Knowles BB. Characterization of the major apolipoproteins secreted by two human hepatoma cell lines. Biochemistry. 1981 Dec 8; 20(25):7089-96.
    View in: PubMed
  167. Zannis VI, Breslow JL. Human very low density lipoprotein apolipoprotein E isoprotein polymorphism is explained by genetic variation and posttranslational modification. Biochemistry. 1981 Feb 17; 20(4):1033-41.
    View in: PubMed
  168. Zannis VI, Just PW, Breslow JL. Human apolipoprotein E isoprotein subclasses are genetically determined. Am J Hum Genet. 1981 Jan; 33(1):11-24.
    View in: PubMed
  169. Zannis VI, Breslow JL, Katz AJ. Isoproteins of human apolipoprotein A-I demonstrated in plasma and intestinal organ culture. J Biol Chem. 1980 Sep 25; 255(18):8612-7.
    View in: PubMed
  170. Zannis VI, Breslow JL. Characterization of a unique human apolipoprotein E variant associated with type III hyperlipoproteinemia. J Biol Chem. 1980 Mar 10; 255(5):1759-62.
    View in: PubMed
  171. Zannis VI, Gudas LJ, Martin DW. Characterization of the subunits of purine nucleoside phosphorylase from cultured normal human fibroblasts. Biochem Genet. 1979 Aug; 17(7-8):621-30.
    View in: PubMed
  172. Zannis VI, Kirsch JF. Effects of substituents on the rates of deacylation of substituted benzoyl papains. Role of a carboxylate residue in the catalytic mechanism. Biochemistry. 1978 Jun 27; 17(13):2669-74.
    View in: PubMed
  173. Zannis VI, Gudas LJ, Doyle D, Martin DA. Purification and characterization of hypoxanthine-guanine phosphoribosyl transferase from cultured HTC cells. Adv Exp Med Biol. 1977; 76A:162-71.
    View in: PubMed
Vassilis's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
BU Co-Authors
_
Similar BU People
_
Same Department